Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRYNOVIN vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
Adult: 150 mg orally twice daily.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Terminal elimination half-life is 12 hours in patients with normal renal function; prolonged to 24-48 hours in moderate to severe renal impairment (Cr Cl < 30 m L/min).
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Primarily metabolized via glucuronidation by UGT1A9 and UGT2B7; minor metabolism by CYP3A4.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Renal excretion accounts for 70% of the administered dose as unchanged drug; biliary/fecal excretion accounts for 30%.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
85% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
Approximately 90–95% bound, primarily to albumin.
1.5 L/kg, indicating extensive tissue distribution and penetration into peripheral compartments.
0.46–0.64 L/kg; indicates distribution into total body water.
Oral: 75% (range: 60-90%) with minimal first-pass metabolism; intravenous: 100%.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Cr Cl 30-59 m L/min: 75 mg twice daily; Cr Cl 15-29 m L/min: 50 mg twice daily; Cr Cl <15 m L/min or dialysis: 25 mg once daily.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh A: no adjustment; Child-Pugh B: 75 mg twice daily; Child-Pugh C: 50 mg twice daily.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Children ≥12 years and ≥40 kg: 150 mg twice daily; <40 kg: 5 mg/kg/dose twice daily (max 150 mg/dose).
Not established; safety and efficacy not studied in pediatric patients.
No specific dose adjustment, but monitor renal function; start at lower end of dosing range if renal impairment.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
None.
None
Ketoacidosis: Monitor for signs of ketoacidosis, including euglycemic ketoacidosis,Lower limb amputation: Consider risk factors prior to initiation; monitor for signs of infection or ulceration
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Severe renal impairment (e GFR <30 m L/min/1.73 m²) or end-stage renal disease on dialysis,History of serious hypersensitivity reaction to brynoxin or any excipient in the formulation
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid grapefruit and grapefruit juice due to CYP3A4 inhibition. Avoid alcohol as it may increase hepatotoxicity risk. Take with food to reduce gastrointestinal upset.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation signal; monitor fetal growth. Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties) at delivery if used near term.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Excreted in breast milk in low amounts (M/P ratio 0.2–0.4). Considered compatible with breastfeeding; monitor infant for sedation or gastrointestinal effects.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
Due to increased volume of distribution and enhanced hepatic clearance in second and third trimesters, the dose may need to be increased by 20–40% to maintain therapeutic plasma concentrations. Therapeutic drug monitoring (trough levels) recommended every 2 weeks with target range 5–15 mcg/m L. Postpartum: reduce dose to pre-pregnancy level within first week.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Monitor renal function and electrolytes before and during therapy. Use with caution in patients with pre-existing cardiac disease due to risk of QT prolongation. Adjust dose in hepatic impairment (Child-Pugh B or C). Contraindicated with strong CYP3A4 inducers.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take exactly as prescribed; do not skip doses or double up.,Avoid grapefruit and grapefruit juice during treatment.,Report any signs of infection, unusual bruising, or yellowing of skin or eyes.,Use effective contraception during treatment and for 3 months after last dose.,Do not drive if you experience dizziness or blurred vision.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
No interactions on record
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRYNOVIN vs CHLORZOXAZONE, answered by our medical review team.
BRYNOVIN is a Opioid Partial Agonist that works by Brynoxin is a potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), reducing renal glucose reabsorption and lowering blood glucose levels independently of insulin.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRYNOVIN and CHLORZOXAZONE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRYNOVIN is: Adult: 150 mg orally twice daily.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRYNOVIN and CHLORZOXAZONE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRYNOVIN is classified as Category C. First trimester: Human data limited; animal studies show embryotoxicity at supra-therapeutic doses. Avoid unless benefit outweighs risk. Second trimester: No specific malformation . CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.